Literature DB >> 25943588

Fractalkine neutralization improves cardiac function after myocardial infarction.

Xiaosong Gu1,2, Jiang Xu1, Xiao-Ping Yang1, Edward Peterson3, Pamela Harding1.   

Abstract

NEW
FINDINGS: What is the central question of this study? What is the cardioprotective role of fractalkine neutralization in heart failure and what are the mechanisms responsible? What is the main finding and its importance? The concentration of fractalkine is increased in the left ventricle of mice with myocardial infarction, similar to the increases in plasma from heart failure patients. The present study shows a clear beneficial effect of neutralizing fractalkine in a model of myocardial infarction, which results in increased survival. Such an approach may be worthwhile in human patients. Concentrations of the chemokine fractalkine (FKN) are increased in patients with chronic heart failure, and our previous studies show that aged mice lacking the prostaglandin E2 EP4 receptor subtype (EP4-KO) have increased cardiac FKN, with a phenotype of dilated cardiomyopathy. However, how FKN participates in the pathogenesis of heart failure has rarely been studied. We hypothesized that FKN contributes to the pathogenesis of heart failure and that anti-FKN treatment prevents heart failure induced by myocardial infarction (MI) more effectively in EP4-KO mice. Male EP4-KO mice and wild-type littermates underwent sham or MI surgery and were treated with an anti-FKN antibody or control IgG. At 2 weeks post-MI, echocardiography was performed and hearts were excised for determination of infarct size, immunohistochemistry and Western blot of signalling molecules. Given that FKN protein levels in the left ventricle were increased to a similar extent in both strains after MI and that anti-FKN treatment improved survival and cardiac function in both strains, we subsequently used only wild-type mice to examine the mechanisms whereby anti-FKN is cardioprotective. Myocyte cross-sectional area and interstitial collagen fraction were reduced after anti-FKN treatment, as were macrophage migration and gelatinase activity. Activation of ERK1/2 and p38 MAPK were reduced after neutralization of FKN. In vitro, FKN increased fibroblast proliferation. In conclusion, increased FKN contributes to heart failure after MI. This effect is not exacerbated in EP4-KO mice, suggesting that there is no link between FKN and lack of EP4. Overall, inhibition of FKN may be important to preserve cardiac function post-MI.
© 2015 The Authors. Experimental Physiology © 2015 The Physiological Society.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25943588      PMCID: PMC4686137          DOI: 10.1113/EP085104

Source DB:  PubMed          Journal:  Exp Physiol        ISSN: 0958-0670            Impact factor:   2.969


  30 in total

1.  Cloning and characterization of a new type of mouse chemokine.

Authors:  D L Rossi; G Hardiman; N G Copeland; D J Gilbert; N Jenkins; A Zlotnik; J F Bazan
Journal:  Genomics       Date:  1998-01-15       Impact factor: 5.736

Review 2.  Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association.

Authors:  Alan S Go; Dariush Mozaffarian; Véronique L Roger; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Sheila Franco; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Mark D Huffman; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; David Magid; Gregory M Marcus; Ariane Marelli; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Michael E Mussolino; Graham Nichol; Nina P Paynter; Pamela J Schreiner; Paul D Sorlie; Joel Stein; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2013-01-01       Impact factor: 29.690

3.  Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation.

Authors:  Y Pan; C Lloyd; H Zhou; S Dolich; J Deeds; J A Gonzalo; J Vath; M Gosselin; J Ma; B Dussault; E Woolf; G Alperin; J Culpepper; J C Gutierrez-Ramos; D Gearing
Journal:  Nature       Date:  1997-06-05       Impact factor: 49.962

4.  Coronary artery disease as the cause of incident heart failure in the population.

Authors:  K F Fox; M R Cowie; D A Wood; A J Coats; J S Gibbs; S R Underwood; R M Turner; P A Poole-Wilson; S W Davies; G C Sutton
Journal:  Eur Heart J       Date:  2001-02       Impact factor: 29.983

5.  A role for fractalkine and its receptor (CX3CR1) in cardiac allograft rejection.

Authors:  L A Robinson; C Nataraj; D W Thomas; D N Howell; R Griffiths; V Bautch; D D Patel; L Feng; T M Coffman
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

6.  Fractalkine levels are elevated early after PCI-treated ST-elevation myocardial infarction; no influence of autologous bone marrow derived stem cell injection.

Authors:  Ida Unhammer Njerve; Svein Solheim; Ketil Lunde; Pavel Hoffmann; Harald Arnesen; Ingebjørg Seljeflot
Journal:  Cytokine       Date:  2014-06-11       Impact factor: 3.861

7.  Cytokine expression profiling of the myocardium reveals a role for CX3CL1 (fractalkine) in heart failure.

Authors:  Cathrine Husberg; Ståle Nygård; Alexandra Vanessa Finsen; Jan Kristian Damås; Arnoldo Frigessi; Erik Oie; Anne Waehre; Lars Gullestad; Pål Aukrust; Arne Yndestad; Geir Christensen
Journal:  J Mol Cell Cardiol       Date:  2008-05-28       Impact factor: 5.000

Review 8.  Post-infarction inflammation and left ventricular remodeling: a double-edged sword.

Authors:  Toshihisa Anzai
Journal:  Circ J       Date:  2013-01-29       Impact factor: 2.993

9.  Sdc1 overexpression inhibits the p38 MAPK pathway and lessens fibrotic ventricular remodeling in MI rats.

Authors:  Juan Lei; Shengneng Xue; Wei Wu; Shuxian Zhou; Yuling Zhang; Guiyi Yuan; Jingfeng Wang
Journal:  Inflammation       Date:  2013-06       Impact factor: 4.092

10.  Left and right ventricle late remodeling following myocardial infarction in rats.

Authors:  Ivanita Stefanon; María Valero-Muñoz; Aurélia Araújo Fernandes; Rogério Faustino Ribeiro; Cristina Rodríguez; Maria Miana; José Martínez-González; Jessica S Spalenza; Vicente Lahera; Paula F Vassallo; Victoria Cachofeiro
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

View more
  11 in total

1.  Prostaglandin E2 and an EP4 receptor agonist inhibit LPS-Induced monocyte chemotactic protein 5 production and secretion in mouse cardiac fibroblasts via Akt and NF-κB signaling.

Authors:  Timothy D Bryson; Jacob Ross; Edward Peterson; Pamela Harding
Journal:  Prostaglandins Other Lipid Mediat       Date:  2019-06-20       Impact factor: 3.072

2.  Overexpression of prostaglandin E2 EP4 receptor improves cardiac function after myocardial infarction.

Authors:  Timothy D Bryson; Xiaosong Gu; Remonda M Khalil; Safa Khan; Liping Zhu; Jiang Xu; Edward Peterson; Xiao-Ping Yang; Pamela Harding
Journal:  J Mol Cell Cardiol       Date:  2018-03-06       Impact factor: 5.000

3.  Inflammatory Macrophage Expansion in Pulmonary Hypertension Depends upon Mobilization of Blood-Borne Monocytes.

Authors:  Jonathan Florentin; Emilie Coppin; Sathish Babu Vasamsetti; Jingsi Zhao; Yi-Yin Tai; Ying Tang; Yingze Zhang; Annie Watson; John Sembrat; Mauricio Rojas; Sara O Vargas; Stephen Y Chan; Partha Dutta
Journal:  J Immunol       Date:  2018-04-09       Impact factor: 5.422

Review 4.  Chemokines in Myocardial Infarction.

Authors:  Bijun Chen; Nikolaos G Frangogiannis
Journal:  J Cardiovasc Transl Res       Date:  2020-05-15       Impact factor: 4.132

5.  Parenchymal and Stromal Cells Contribute to Pro-Inflammatory Myocardial Environment at Early Stages of Diabetes: Protective Role of Resveratrol.

Authors:  Monia Savi; Leonardo Bocchi; Roberto Sala; Caterina Frati; Costanza Lagrasta; Denise Madeddu; Angela Falco; Serena Pollino; Letizia Bresciani; Michele Miragoli; Massimiliano Zaniboni; Federico Quaini; Daniele Del Rio; Donatella Stilli
Journal:  Nutrients       Date:  2016-11-16       Impact factor: 5.717

6.  In vivo administration of urolithin A and B prevents the occurrence of cardiac dysfunction in streptozotocin-induced diabetic rats.

Authors:  Monia Savi; Leonardo Bocchi; Pedro Mena; Margherita Dall'Asta; Alan Crozier; Furio Brighenti; Donatella Stilli; Daniele Del Rio
Journal:  Cardiovasc Diabetol       Date:  2017-07-06       Impact factor: 9.951

7.  CX3CR1 knockout aggravates Coxsackievirus B3-induced myocarditis.

Authors:  Irene Müller; Kathleen Pappritz; Konstantinos Savvatis; Kerstin Puhl; Fengquan Dong; Muhammad El-Shafeey; Nazha Hamdani; Isabell Hamann; Michel Noutsias; Carmen Infante-Duarte; Wolfgang A Linke; Sophie Van Linthout; Carsten Tschöpe
Journal:  PLoS One       Date:  2017-08-11       Impact factor: 3.240

8.  Neutrophil extracellular traps and monocyte subsets at the culprit lesion site of myocardial infarction patients.

Authors:  Andreas Mangold; Thomas M Hofbauer; Anna S Ondracek; Tyler Artner; Thomas Scherz; Walter S Speidl; Konstantin A Krychtiuk; Roela Sadushi-Kolici; Johannes Jakowitsch; Irene M Lang
Journal:  Sci Rep       Date:  2019-11-08       Impact factor: 4.379

9.  CX3CR1 is a prerequisite for the development of cardiac hypertrophy and left ventricular dysfunction in mice upon transverse aortic constriction.

Authors:  Christina Katharina Weisheit; Jan Lukas Kleiner; Maria Belen Rodrigo; Sven Thomas Niepmann; Sebastian Zimmer; Georg Daniel Duerr; Mark Coburn; Christian Kurts; Stilla Frede; Lars Eichhorn
Journal:  PLoS One       Date:  2021-01-07       Impact factor: 3.240

10.  The Fractalkine Receptor CX3CR1 Links Lymphocyte Kinetics in CMV-Seropositive Patients and Acute Myocardial Infarction With Adverse Left Ventricular Remodeling.

Authors:  Luke Spray; Catherine Park; Suzanne Cormack; Ashfaq Mohammed; Pedram Panahi; Stephen Boag; Karim Bennaceur; Kateryna Sopova; Gavin Richardson; Verena M Stangl; Lavinia Rech; Peter P Rainer; Gustavo Campos Ramos; Ulrich Hofmann; Konstantinos Stellos; Ioakim Spyridopoulos
Journal:  Front Immunol       Date:  2021-05-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.